QNRX
Quoin Pharmaceuticals Ltd DRCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.58M
P/E Ratio
—
EPS
$-10.07
Beta
1.75
52W High
$23.50
52W Low
$4.59
50-Day MA
$6.43
200-Day MA
$9.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. By utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of existing pharmaceuticals, positioning itself as a key player in the specialty pharmaceuticals sector. Quoin's robust pipeline includes promising therapies aimed at critical health conditions, highlighting its potential for substantial clinical advancements and market impact. The company is dedicated to creating value for both patients and investors through strategic collaborations and cutting-edge research initiatives.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.36M |
| Operating Margin | 0.00% |
| Return on Equity | -231.20% |
| Return on Assets | -76.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.76 |
| Price-to-Book | 1.09 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.01M |
| Float | $50.45M |
| % Insiders | 2.63% |
| % Institutions | 50.74% |
Historical Volatility
HV 10-Day
53.05%
HV 20-Day
71.05%
HV 30-Day
64.80%
HV 60-Day
90.73%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($29.75 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026